Study on the Correlation Between Serum PRMT5 Level and Cardiac Structural and Functional Indicators in Patients With Heart Failure
试验速览
- 阶段
- 不适用
- 状态
- Enrolling By Invitation
- 发起方
- 入组人数
- 50
- 试验地点
- 1
- 主要终点
- Serum PRMT5 level at baseline
研究概览
简要总结
Pathological cardiac hypertrophy is characterized by abnormal cardiomyocyte metabolism, reduced myocardial contractility, and dysregulated synthesis of myocardial contractile proteins. This pathological process leads to progressive impairment of cardiac function and ultimately progresses to heart failure. Previous studies have demonstrated that PRMT5 exerts a significant inhibitory effect on heart failure, yet its clinical significance in the context of heart failure remains undefined. In this study, we hypothesized that serum PRMT5 may serve as a biomarker to predict cardiac structural parameters and functional indices. Therefore, we aim to analyse the correlation between serum PRMT5 levels and the following parameters-LVPWs, LVPWd, LVIDs, LVIDd, IVSTs, IVSTd, EF, FS, LVMi and RWT on the first day when participants are enrolled in this study.
详细描述
The aim of this study is to collect blood samples from both healthy controls and heart failure patients and to clarify the correlation between serum PRMT5 levels on the first day of enrollment and cardiac ultrasound indicators. Serum PRMT5 levels are measured by means of enzyme-linked immunosorbent assay (ELISA). Left ventricular posterior wall thickness at end-systole (LVPWs), Left ventricular posterior wall thickness at end-diastole (LVPWd), left ventricular internal diameter at end-systole (LVIDs), left ventricular internal diameter at end-diastole (LVIDd), interventricular septum at end-systole (IVSTs) and interventricular septal septum at end-diastole (IVSTd) are measured on the first day of enrollment via echocardiography. Ejection fraction (EF), fractional shortening (FS), left ventricular mass index (LVMi), and relative wall thickness (RWT) are subsequently calculated based on LVIDd, LVPWd, and IVSTd values. Finally, the correlations between serum PRMT5 levels and the following indicators are analyzed: LVPWs, LVPWd, LVIDs, LVIDd, IVSTs, IVSTd, EF, FS, LVMi and RWT.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy group: Aged ≥18 years (both sexes), systolic blood pressure (SBP) ≤120 mmHg and diastolic blood pressure (DBP) ≤80 mmHg, no history of cardiovascular diseases, ejection fraction (EF) ≥50%.
- •Heart failure group: Aged ≥18 years (both sexes), EF ≤50%.
排除标准
- •Exclusion criteria for healthy people: people with other underlying diseases or congenital diseases are not included in the study.
- •Exclusion criteria for patients with heart failure: patients with heart failure other metabolic diseases or congenital diseases were excluded from the study.
结局指标
主要结局
Serum PRMT5 level at baseline
时间窗: Baseline (day of informed consent agreement and blood sampling)
Serum PRMT5 level is analysed at the day of informed consent agreement and blood sampling
IVSTd at baseline
时间窗: Baseline
Interventricular septum at diastolic state is measured at the day of informed consent agreement and cardiac ultrasound examination
LVIDs level at baseline
时间窗: Baseline
Left ventricular internal diameter at systolic state is measured at the day of informed consent agreement and cardiac ultrasound examination
LVPWs level at baseline
时间窗: Baseline
left ventricular posterior wall at systolic state is measured at the day of informed consent agreement and cardiac ultrasound examination
IVSTs at baseline
时间窗: Baseline
Interventricular septum at systolic state is measured at the day of informed consent agreement and cardiac ultrasound examination
LVMi at baseline
时间窗: Baseline
Left ventricular mass index is calculated according to the formula below: 1. LVMi(g/m\^2)=LVM/BSA; 2. LVM(g)=LVM=0.8×1.04×\[(LVIDd+IVSd+LVPWd)\^3-LVIDd\^3\]+0.6; 3. BSA(m\^2)=0.007184×W\^0.425×H\^0.725 (W: Weight, kg; H: Height, cm)
LVIDd level at baseline
时间窗: Baseline
Left ventricular internal diameter at diastolic state is measured at the day of informed consent agreement and cardiac ultrasound examination
LVPWd level at baseline
时间窗: Baseline
left ventricular posterior wall at diastole state is measured at the day of informed consent agreement and cardiac ultrasound examination
EF at baseline
时间窗: Baseline
Ejection fraction is calculated according to the formula below: 1. EF=(LVEDV-LVESV)/LVEDV\*100%; 2. LVEDV=(7.0\*LVIDd\^3)/(2.4+LVIDd) 3. LVESV=(7.0\*LVIDs\^3)/(2.4+LVIDs)
FS at baseline
时间窗: Baseline
Fractional shortening is calculated based on the formula below: FS=(LVIDd-LVIDs)/LVIDd\*100%
RWT at baseline
时间窗: Baseline
Relative wall thickness is calculated according to the formula below: RWT=2\*(IVSd+LVPWd)/LVIDd
次要结局
未报告次要终点
研究者
Cai Sidong
assistant research fellow
The University of Hong Kong-Shenzhen Hospital